Up­start GeneTx launch­es, go­ing head to head with Ovid on rare An­gel­man syn­drome

An Illi­nois non­prof­it has launched a start­up de­vel­op­ing a drug to treat An­gel­man syn­drome – the ge­net­ic con­di­tion that’s al­so be­ing tack­led by Je­re­my Levin’s high­er pro­file up­start Ovid Ther­a­peu­tics $OVID.

Levin, who you might know as the for­mer busi­ness de­vel­op­ment chief at Bris­tol-My­ers, was al­so Te­va’s CEO for a brief stint be­fore jump­ing in­to the biotech start­up busi­ness. Ovid, his lat­est ven­ture, just closed a $75 mil­lion IPO last year with a drug to take on An­gel­man syn­drome, a rare dis­ease that af­fects the ner­vous sys­tem.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER